Monotherapy in advanced prostate cancer: an overview

Απλή σελίδα τεκμηρίου
dc.contributor.authorBaltogiannis, D.en
dc.contributor.authorGiannakopoulos, X.en
dc.contributor.authorCharalabopoulos, K.en
dc.contributor.authorSofikitis, N.en
dc.date.accessioned2015-11-24T19:03:53Z
dc.date.available2015-11-24T19:03:53Z
dc.identifier.issn1812-9269-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19941
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/blood/*drug therapy/secondary/surgeryen
dc.subjectAndrogen Antagonists/administration & dosage/*therapeutic useen
dc.subjectAnilides/therapeutic useen
dc.subjectAntineoplastic Agents, Hormonal/administration & dosage/*therapeutic useen
dc.subjectCombined Modality Therapyen
dc.subjectCyproterone Acetate/therapeutic useen
dc.subjectDihydrotestosterone/blooden
dc.subjectEstrogens/administration & dosage/therapeutic useen
dc.subjectFlutamide/therapeutic useen
dc.subjectGonadotropin-Releasing Hormone/agonistsen
dc.subjectHumansen
dc.subjectImidazolidines/therapeutic useen
dc.subjectMaleen
dc.subjectNitrilesen
dc.subjectOrchiectomyen
dc.subject*Palliative Careen
dc.subjectProgesterone Congeners/therapeutic useen
dc.subjectProstatic Neoplasms/blood/*drug therapy/pathology/surgeryen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectTestosterone/blooden
dc.subjectTosyl Compoundsen
dc.titleMonotherapy in advanced prostate cancer: an overviewen
heal.abstractProstate cancer is the second leading malignancy in men associated with an enormous research interest in all aspects of the disease. It is well recognized that the regulation of prostatic growth is a complicated biological process. Further more the androgenic dependence of the advanced prostate cancer is well know and in the last 50 years significant progresses regarding the principle of deprivation of androgens for the treatment of the disease occured. Prostate cancer is now diagnosed in earlier stages and treatment results in increased potential for cure or extension of overall survival. Unfortunately, every treatment for prostate cancer has adverse effects with negative impact in health-related quality of life. Surgical or pharmacological castration has a significant negative impact on quality of life in patients with prostate cancer (loss of sexuality, osteoporosis, and loss of muscle mass, e.g.). Antiandrogen monotherapy is considered to be a treatment in well-informed patients who wish to remain sexually active, can be administered orally, and is well tolerated by patients with prostate cancer. This review is focused on antiandrogen monotherapy in the treatment of advanced prostate cancer.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15494685-
heal.journalNameExp Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2004-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ